Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06606366 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

Study acronym: TARGET
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 6 wordsv6
  2. Enrollment target: 216 to 238
    • Site contact updated
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 2027 to Jun 3, 2027
    • Start date changed from estimate of Feb 2025 to Mar 3, 2025
    • Site details revised
    v4
  4. Site details revisedv3
  5. Primary endpoint revised
    • Eligibility criteria revised
    • Secondary endpoints revised (5)
    • Study title revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Trial Details
NCT Number NCT06606366
Lead Sponsor Centre Antoine Lacassagne
Conditions
(from sponsor)		 Neoplasm Malignant
Related terms Neoplasms
Enrollment 238 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov